Yes, people with early Alzheimer's can now start Leqembi at home with a weekly shot under the skin. Family caregivers can compare that home start with clinic infusions given every two weeks. Leqembi (lecanemab) targets amyloid-beta protein in the brain. It is only for early disease with confirmed amyloid.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can consider either route?
- How do the two starting routes compare?
- What does starting at home actually require?
- What safety checks still apply?
Who can consider either route?
Both routes are only for adults with mild cognitive impairment or mild dementia due to Alzheimer's. Amyloid-beta pathology must be confirmed, generally by PET scan or spinal-fluid testing.
That rule narrows the choice early. A caregiver can ask the doctor whether memory symptoms fit the mild stage. Then they can ask whether amyloid testing has confirmed eligibility.
How do the two starting routes compare?
Eisai and Biogen announced on July 13, 2026 that the FDA approved LEQEMBI IQLIK as a weekly injection that can start treatment at home. The clinic route remains an infusion given every two weeks.
For caregivers, the trade is travel and clinic time against giving shots. Home shots still need training, storage, and a clear weekly routine. Infusions keep dosing in clinical hands but require repeated visits.
- Home start: 500 mg weekly, given as two consecutive 250-mg autoinjector shots, each delivered in about 15 seconds, according to the BioArctic partner release
- Clinic start: lecanemab 10 mg/kg every two weeks, infused over about one hour
What does starting at home actually require?
Home use does not begin alone on day one. A patient or caregiver may give the shot at home only after at least two consecutive weekly doses under direct provider supervision and approval, stated in FDA prescribing information. That supervised period lets the care team teach technique and watch tolerance.
Approval to continue at home must come from the provider. After 18 months of initiation treatment, maintenance is 360 mg under the skin once weekly or continued IV dosing. Caregivers planning long term should ask which maintenance path the clinic uses. They should also confirm who orders refills and follow-up visits.
What safety checks still apply?
Home dosing does not remove the risk of ARIA, meaning brain swelling or bleeding. The label carries a boxed warning for ARIA, highest in people with two copies of ApoE ε4. ApoE genetic testing is recommended before starting.
MRI monitoring still applies regardless of route. The schedule includes a baseline MRI plus follow-ups after about 1, 2, 3, and 6 months to detect ARIA early, described in the Drugs.com Leqembi monograph. Keep each MRI appointment even when memory seems stable and shots feel routine. Ask the prescribing team how to report headache, confusion, dizziness, vision changes, or other new symptoms promptly.
You Might Also Like
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How Primary Care Patients Can Avoid Overreading the Headline
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How Primary Care Patients Can Avoid Overreading the Headline
- How Solo Family Caregivers Can Discuss Alzheimer’s Disease With the Care Team
